|
WO2021076691A1
|
|
Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
|
|
WO2021076688A1
|
|
Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
|
|
US2021008049A1
|
|
Indanes as pd-l1 inhibitors
|
|
US2021002229A1
|
|
Compounds for treatment of pd-l1 diseases
|
|
US2020383979A1
|
|
Triaryl compounds for treatment of pd-l1 diseases
|
|
WO2020191240A1
|
|
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
|
|
US10792360B1
|
|
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
|
|
WO2020123582A1
|
|
Cxcr7 inhibitors for the treatment of cancer
|
|
WO2020112961A1
|
|
Capsule formulations
|
|
WO2020047035A1
|
|
Methods of treating cancer with small molecule pd-l1 inhibitors
|
|
US2020069673A1
|
|
Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
|
|
KR20210018906A
|
|
Administration and effects of C5A antagonists on ANCA-associated vasculitis
|
|
KR20200139751A
|
|
Prodrugs of fused-bicyclic C5aR antagonists
|
|
US2019275015A1
|
|
Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
|
|
US2019269664A1
|
|
Methods of treating solid tumors with ccr2 antagonists
|
|
US2019282555A1
|
|
Indane-amines as PD-L1 antagonists
|
|
WO2019136368A2
|
|
Methods of treating solid tumors with ccr2 antagonists
|
|
CA3087701A1
|
|
Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
|
|
AU2018388657A1
|
|
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
|
|
CN111788185A
|
|
Diaryl substituted 6,5 fused ring compounds as C5a inhibitors
|
